Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 8Lung Neoplasms 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Multiple Myeloma 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Glioblastoma 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Glioma 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Burkitt Lymphoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroblastoma 2Meningioma 2Lymphoma, B-Cell 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Cyclophosphamide 2sargramostim 1iberdomide 1fludarabine 1dinutuximab 1Topotecan 1Magnetic Resonance Spectroscopy 1Influenza Vaccines 1Colony-Stimulating Factors 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ganglioneuroblastoma × Magnetic Resonance Spectroscopy × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡